Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular Carcinoma

Not Applicable

• Conditions: Hepatocellular Carcinoma

• Registration Number: JPRN-UMIN000005697
• Lead Sponsor: Chiba University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with a history of malignancy. 2) Corresponding to the sever heart disease. 3) Active clinically-serious infections. 4) History of HIV infection. 5) Hemodialysis. 6) Clinical or radiological evidence of CNS metastases. 7) Uncontrollable massive ascites, pleural effusion. 8) Clinically-significant gastrointestinal bleeding within 4 weeks prior to study entry. 9) Severe allergy for fluoropyrimidines. 10) HBV-DNA positive and not being treated with nucleotide analogues. 11) Anticoagulant therapy with warfarin potassium. 12) During treatment with Tegafur gimeracil oteracil potassium, or within 7 days after discontinuation. 13) Use Sho-saiko-to. 14) Use oral phenytoin. 15) Severe thyroid disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified